CIBC Asset Management Inc Boosts Stock Holdings in Merck & Co., Inc. $MRK

CIBC Asset Management Inc boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 51.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 720,718 shares of the company’s stock after purchasing an additional 245,419 shares during the period. CIBC Asset Management Inc’s holdings in Merck & Co., Inc. were worth $75,863,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $3,997,933,000. DLD Asset Management LP raised its holdings in shares of Merck & Co., Inc. by 30.1% in the 3rd quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock worth $3,986,675,000 after purchasing an additional 11,000,000 shares during the period. Jennison Associates LLC purchased a new position in shares of Merck & Co., Inc. in the 4th quarter worth about $585,192,000. Invesco Ltd. raised its holdings in shares of Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the period. Finally, Ameriprise Financial Inc. raised its holdings in shares of Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock worth $1,336,877,000 after purchasing an additional 2,735,459 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck said the FDA granted Breakthrough Therapy Designation for calderasib in combination with Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant non-small cell lung cancer patients, which may speed development and improve the drug’s commercial outlook. Article Title
• Positive Sentiment: Moderna and Merck presented five-year data for their melanoma combination therapy, showing a 49% reduction in recurrence or death risk versus Keytruda alone, reinforcing confidence in Merck’s oncology pipeline and Keytruda’s franchise. Article Title
• Positive Sentiment: Reports highlighted possible new EU approval momentum for Keytruda, which would expand the drug’s reach outside the U.S. and support future revenue growth. Article Title
• Positive Sentiment: Merck announced a quarterly dividend, reinforcing its shareholder-return profile and signaling financial stability. Article Title
• Positive Sentiment: Merck is also strengthening its capital structure with a notes offering, which may improve liquidity and financial flexibility. Article Title
• Neutral Sentiment: Merck will participate in the Goldman Sachs Global Healthcare Conference, a routine investor event that could provide updates but does not by itself change fundamentals. Article Title
• Neutral Sentiment: Commentary from Jim Cramer noting that Merck’s cancer dominance has been challenged by J&J is more of a competitive observation than a direct catalyst, but it underscores pressure in oncology. Article Title
• Neutral Sentiment: Reuters reported Merck is discussing whether its COVID antiviral molnupiravir could be used in the Ebola response; this is potentially meaningful, but still exploratory. Article Title

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on MRK. Cantor Fitzgerald raised their target price on shares of Merck & Co., Inc. from $116.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Barclays began coverage on shares of Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 target price on the stock. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a report on Monday, March 30th. Finally, Wall Street Zen downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus price target of $128.18.

Merck & Co., Inc. Price Performance

MRK stock opened at $115.89 on Wednesday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. Merck & Co., Inc. has a 52-week low of $75.43 and a 52-week high of $125.14. The stock’s 50 day moving average is $116.42 and its two-hundred day moving average is $111.81. The company has a market capitalization of $286.23 billion, a PE ratio of 32.65, a P/E/G ratio of 2.59 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The company had revenue of $16.29 billion for the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the previous year, the business earned $2.22 EPS. Merck & Co., Inc.’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts predict that Merck & Co., Inc. will post 5.16 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 8th. Stockholders of record on Monday, June 15th will be given a $0.85 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. Merck & Co., Inc.’s payout ratio is presently 95.77%.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.